 Pieris will receive 10 million upfront and be entitled to receive additional milestone payments and tiered royalties Boston Pharmaceuticals will be primarily responsible for development of the program, with both parties collaborating during the investigational new drug IND-enabling stage BOSTON and CAMBRIDGE, MA ACCESSWIRE April 26, 2021 Pieris Pharmaceuticals, Inc. NASDAQ:PIRS and Boston Pharmaceuticals today announced that the companies have entered into an exclusive product license agreement to develop PRS-342, a 4-1BBGPC3 preclinical immuno-oncology Anticalin-antibody bispecific fusion protein. Under the terms of the agreement, Boston Pharmaceuticals has exclusively licensed worldwide rights to PRS-342. 